PF-4708671, with the CAS number 1255517-76-0, is a small molecule that serves as a selective inhibitor of the protein kinase mTOR (mechanistic target of rapamycin). This compound is primarily investigated for its potential therapeutic applications in cancer treatment and other diseases characterized by dysregulated mTOR signaling. PF-4708671 exhibits a high degree of specificity for mTOR, which is a central regulator of cell growth, proliferation, and survival. The inhibition of mTOR by PF-4708671 can lead to reduced protein synthesis and cell cycle arrest, making it a candidate for combination therapies in oncology. Additionally, the compound has been studied for its effects on metabolic processes and its potential role in addressing conditions such as obesity and diabetes. As with many investigational drugs, the pharmacokinetics, bioavailability, and safety profile of PF-4708671 are subjects of ongoing research to better understand its efficacy and potential side effects in clinical settings.

PF-4708671

Find at CymitQuimica all products linked to CAS 1255517-76-0. Enter now to get more information

PF 4708671

PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) .In cell-free assays, PF-4708671 is potent for S6K1(Ki50=20 nM, IC50=160 nM).

CAS 1255517-76-0: PF-4708671

PF 4708671

Ref: 3D-FE101574

PF-4708671

Ref: 54-BISN0176

PF-4708671

Ref: TM-T2002

PF-4708671

Ref: 7W-GK4153

PF-4708671

Ref: 4Z-PF-0020

2-[[4-(5-Ethylpyrimidin-4-yl)piperazin-1-yl]methyl]-5-(trifluoromethyl)-1H-benzo[d]imidazole

Ref: IN-DA009CE5